Company Filing History:

26 out of 44

Tanox Biosystems, Inc.

patents

Years Active: 1987-2000

Loading Chart...

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6129916 - Method of Increasing activation on proliferation of T cells using (2000-10-10),

2. 6117982 - Conjugates of microbeads and antibodies specific for T lymphocytes and (2000-09-12),

3. 6106835 - Modified binding molecules specific for T or B lymphocytes and their use (2000-08-22),

4. 5872222 - Conjugates of polymers and antibodies specific for T lymphocytes, and (1999-02-16),

5. 5866129 - Method of producing an antibody with a peptide corresponding to (1999-02-02),

6. 5854400 - Monoclonal antibodies which neutralize HIV-1 infection (1998-12-29),

7. 5723125 - Hybrid with interferon-alpha and an immunoglobulin Fc linked through a (1998-03-03),

8. 5690934 - Peptides relating to the extracellular membrane-bound segment of human (1997-11-25),

9. 5670626 - Allergen-specific human IgA monoclonal antibodies for mucosal (1997-09-23),

10. 5614611 - Humanized monoclonal antibodies binding to IgE-bearing B cells but not (1997-03-25),

11. 5543144 - Treating hypersensitivities with anti-IGE monoclonal antibodies which (1996-08-06),

12. 5514776 - Peptides representing antigenic epitopes of dog IgE present on B cell (1996-05-07),

13. 5484907 - Nucleotides coding for the extracellular membrane-bound segment of IgA (1996-01-16),

14. 5362643 - Antibodies to epitopes present on membrane-bound but not secreted IGA (1994-11-08),

15. 5342924 - Extracellular segments of human .epsilon. immunoglobulin anchoring (1994-08-30),

Title: Innovations and Contributions of Tse W Chang

Introduction

Tse W Chang, based in Houston, TX, is an accomplished inventor with an impressive portfolio of 32 patents. His work primarily focuses on immunology and the advancement of T cell activation methods, which play a critical role in the field of immunotherapy.

Latest Patents

One of Tse W Chang's latest patents introduces a method for increasing activation on the proliferation of T cells through innovative conjugates. These conjugates consist of a polymer backbone or microbead combined with binding molecules such as Fv, Fab, or F(ab').sub.2 fragments of monoclonal antibodies or whole antibodies. Notably, these are designed to avoid potential adverse effects associated with antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated cytolysis, while remaining specific to T cell surface antigens including CD3, TCR, CD4, CD8, or CD28. His work emphasizes the utility of cross-linked dextran, ficoll, latex, or agarose in creating effective microbeads, typically ranging from 1 to 10 µm, that can be utilized in vivo. This innovative approach seeks not only to induce T cell proliferation and immune stimulation but also to enhance the antibody response to administered antigens.

Career Highlights

Throughout his career, Tse W Chang has contributed significantly to the field of biotechnology, particularly through his engagements with companies like Tanox Biosystems, Inc. and Tanox, Inc. His patents reflect years of dedicated research and innovation in understanding T cell dynamics and improving therapeutic interventions for various diseases.

Collaborations

Tse W Chang has collaborated with notable individuals in the field, including Nancy T Chang and Michael S Fung. These partnerships have further enriched his research endeavors, promoting advancements in immunological techniques and methodologies.

Conclusion

Tse W Chang's contributions to immunology through his patents and collaborative efforts illustrate the vital role of innovative thinking in advancing medical science. His inventions not only enhance our understanding of T cell activation but also have the potential to shape future therapeutic applications, reinforcing the importance of continued research and development in the field.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com